Skip to main content

Artelo Biosciences, Inc.

ARTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001621221

No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Artelo Biosciences, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of ARTL: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders18115−2
Shares1.47M15.0K1.40M−52.8K (−3.6%)
Value$659.0K$7.00K$442.8K−$209.2K (−32.1%)

1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (1)

Institutions that held Artelo Biosciences, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to ARTL in Q2 2022
InstitutionSharesValue% of portfolio
StoneX Group Inc.15,000$4.75K0.00%

Sold out (3)

Institutions that held Artelo Biosciences, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of ARTL in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Renaissance Technologies LLC182,619$82.0K
HRT Financial LP27,952$12.0K
Two Sigma Securities, LLC18,227$8.00K

Not filed for Q2 2022 yet (1)

Institutions that held Artelo Biosciences, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ARTL in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Keystone Wealth Partners15,000$7.00K